Samsung Takes Jab At Bayer, Regeneron Eye Patents
Samsung's pharmaceutical unit wants a London judge to nix two patents owned by its rivals that help treat eye disorders, arguing that they are both invalid as it prepares to launch...To view the full article, register now.
Already a subscriber? Click here to view full article